Eli Lilly Gains Rights to AI-Discovered Drugs in $2.75B Deal with Insilico

The new agreement expands Eli Lilly's portfolio by including specific preclinical AI-identified candidates, not just broader development commitments. This integration signifies a strategic move toward more targeted AI-driven drug commercialization. Next, Lilly may initiate clinical trials on these assets, advancing AI's role in therapeutic development.